Can Mavacamten Help You Exercise More?
Part of Heart & circulation clinical trials.
This study looks at whether taking mavacamten for at least 12 weeks helps people with a certain type of heart disease (hypertrophic obstructive cardiomyopathy) exercise better. You'll have tests to check your heart's function and safety during exercise.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have hypertrophic obstructive cardiomyopathy (a condition where the heart muscle is thickened and blocks blood flow).
- You've been taking mavacamten for at least 12 weeks at the same dose.
- Your heart's pressure gradient is 50 mmHg or less at rest and during stress.
- Your heart's pumping strength (ejection fraction) is 50% or more.
- Your heart failure symptoms are mild (class I or II on the NYHA scale).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how the drug mavacamten affects people with a specific type of heart muscle disease (hypertrophic cardiomyopathy) that causes a blockage. We want to see if the drug helps improve symptoms like shortness of breath or chest pain, and how it works on the heart's valves.
This study tests whether the drug mavacamten (Camzyos) improves blood flow in the heart's small vessels for people with obstructive hypertrophic cardiomyopathy. You will take mavacamten as prescribed and have a PET/CT scan to measure your heart's blood flow reserve.
This study looks at how well mavacamten works in real life for adults with obstructive hypertrophic cardiomyopathy, a condition where the heart muscle is thickened and blocks blood flow. It may help improve symptoms like shortness of breath or chest pain.
This trial tests whether a drug called mavacamten can help people with a specific type of thickened heart muscle (obstructive hypertrophic cardiomyopathy, or oHCM) by improving how the heart uses energy. It aims to understand if this treatment can improve symptoms and function.
This study tracks how mavacamten (a heart medication) works in Japanese patients with obstructive hypertrophic cardiomyopathy—a condition where the heart muscle becomes abnormally thick and blocks blood flow. The trial aims to understand how well the treatment works and how doctors use it in real-world care.
This trial combines a new heart medication (mavacamten) with a procedure called radiofrequency ablation to treat a condition where the heart muscle thickens and blocks blood flow. It is for people who still have symptoms despite standard care.
Hear when a new Cardiomyopathy, Hypertrophic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.